CDSCO panel gives Emcure Pharma waiver on Phase IV CT for Lamivudine plus Dolutegravir

Published On 2022-04-27 12:49 GMT | Update On 2022-04-27 12:49 GMT

New Delhi: Pharmaceutical major, Emcure Pharmaceuticals has got approval from the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization for Phase IV clinical trial waiver of antiviral fixed-dose combination Lamivudine 300 mg plus Dolutegravir 50mg tablets

This came in line with the proposal presented by the firm along with the first PSUR (Periodic Safety Update Report) data.

Dolutegravir-lamivudine is an antiretroviral fixed drug combination tablet. It is approved for initial therapy for the treatment of individuals who have no known or suspected resistance to these two drugs. This fixed drug combination decreases the chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer.

This fixed drug combination of dolutegravir and lamivudine is used alone to treat human immunodeficiency virus (HIV) infection in people who have never been treated with any HIV medications before or in people who have responded well to their HIV medication regimens and have no history of poor response to their past HIV regimens.

Lamivudine is in a class of medications called nucleoside analogue reverse transcriptase inhibitors (NRTIs). Dolutegravir is in a class of medications called integrase strand transfer inhibitors (INSTIs). They work together to reduce the amount of HIV in the blood.

Earlier at 109th SEC meeting for Antimicrobial & Antiviral, the firm presented their proposal before the committee requesting for Phase IV clinical trial waiver. At the same meeting, the firm presented various international studies on the FDC and also informed that this use of the FDC is also recommended in WHO 2021 guidelines before the committee.

In addition, the committee noted that the FDC of Dolutegravir + Lamivudine + Abacavir is already approved. Also, it was noted that as part of the manufacturing and marketing permission the first PSUR of the FDC is likely to be submitted.

Now in continuation, at the 112th SEC meeting for Antimicrobial & Antiviral held on 21.04.2022, the expert panel reviewed the proposal presented by drug maker Emcure Pharmaceuticals along with the first PSUR data of fixed-dose combination Lamivudine 300 mg plus Dolutegravir 50mg tablets.

The committee noted that the FDC is already approved in the US, UK, Australia, Japan, etc., and is also recommended in WHO 2021 guidelines.

After detailed deliberation, the committee recommended the Phase IV clinical trial waiver.

Also Read:Dr. Roddy's gets CDSCO panel nod to study Fosravuconazole L Lysine Ethanolate Capsule

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

CDSCO panel gives Emcure Pharma waiver on Phase IV CT for Lamivudine plus Dolutegravir

Similar News

NPPA Caps Prices of Ipratropium, Sodium Nitroprusside, Two Other Essential Drugs

Akum Pharma Asked to Submit Safety Data for Alzheimer's Drug Combo In Elderly Indian Patients

Aurobindo Pharma net profit drops 10 percent to Rs 824 crore in Q1

MSN Labs Gets CDSCO Panel Nod to Begin Phase III Trial of Cenobamate Tablets, With Safety Caveat

USFDA appoints Sean Keveney as Chief Counsel

Bristol Myers Squibb Breyanzi application accepted for priority review by USFDA for Marginal Zone Lymphoma

Cipla Bommasandra facility gets VAI classification from USFDA

Eli Lilly expands India presence with inauguration of Hyderabad site